Introduction: Dova Pharmaceuticals is a pharmaceutical company that specializes in the development and commercialization of drugs for rare diseases. It is headquartered in Durham, North Carolina, and was founded in 2016. Dova Pharma is dedicated to improving the lives of patients with rare diseases by developing products that address their unmet medical needs. In this article, we will be discussing in-depth about Dova Pharmaceuticals, including its uses, dosage, side effects, interactions, generic, and demographic. Uses: Dova Pharmaceuticals has developed two FDA-approved drugs, Doptelet and Avatrombopag. Doptelet is used to treat thrombocytopenia, which is a condition characterized by low platelet count. It is used in adult patients with chronic liver disease who are scheduled to undergo a medical or dental procedure. Doptelet works by stimulating the production of platelets in the bone marrow, thereby preventing bleeding during the procedure. Avatrombopag is used to treat thrombocytopenia in adult patients with chronic liver disease. It is also used to treat patients with thrombocytopenia who are undergoing surgery. Avatrombopag works by increasing the production of platelets and reducing the risk of bleeding. Dosage: The dosage of Doptelet varies according to the platelet count of the patient. The recommended starting dose is 60 mg orally once daily for five days. After five days, the platelet count should be reassessed. If the platelet count has not increased to the desired level, the treatment can be continued for up to an additional five days. The maximum daily dose of Doptelet should not exceed 120 mg. The recommended dosage of Avatrombopag is 60 mg orally once daily for up to five days. The treatment can be continued for up to an additional five days if the platelet count does not increase to the desired level. The maximum daily dose of Avatrombopag should not exceed 80 mg. Side Effects: The most common side effects of Doptelet include headache, fatigue, insomnia, abdominal pain, nausea, diarrhea, and upper respiratory tract infection. Rare but serious side effects include hemorrhage, pulmonary embolism, and hepatotoxicity. The most common side effects of Avatrombopag include headache, fatigue, nausea, diarrhea, and upper respiratory infection. Serious side effects include hepatotoxicity, thrombotic events, and cataracts. Interactions: Doptelet should not be used with anticoagulants or antiplatelet agents due to the increased risk of bleeding. Doptelet may also interact with drugs that are metabolized by CYP3A4, such as fluconazole and verapamil. Avatrombopag may interact with drugs that are metabolized by CYP2C9, such as warfarin. The combination of Avatrombopag and warfarin may increase the risk of bleeding. Generic: Both Doptelet and Avatrombopag are available as brand-name drugs only. There are currently no generic versions of these drugs available. Demographic: Doptelet and Avatrombopag are approved for use in adult patients with chronic liver disease who are scheduled to undergo a medical or dental procedure. Avatrombopag is also approved for use in patients who are undergoing surgery. Conclusion: Dova Pharmaceuticals is a pharmaceutical company that develops drugs for rare diseases. The company has developed two FDA-approved drugs, Doptelet and Avatrombopag, which are used to treat thrombocytopenia in patients with chronic liver disease. The dosage, side effects, interactions, and demographic of these drugs have been discussed in detail. While these drugs have been shown to be effective in treating thrombocytopenia, they may not be appropriate for everyone. Patients should discuss the risks and benefits of these drugs with their healthcare provider before starting treatment.